Abstract Treatment-resistant epilepsy (TRE) affects 30% of epilepsy patients and is
associated with severe morbidity and increased mortality. Cannabis-based therapies have
been used to treat epilepsy for millennia, but only in the last few years have we begun to
collect data from adequately powered placebo-controlled, randomized trials (RCTs) with
cannabidiol (CBD), a cannabis derivative. Previously, information was limited to case
reports, small series, and surveys reporting on the use of CBD and diverse medical …